VivoSeq
Oncology

Advanced Cancer

16

Pipeline Programs↗

50

Active Trials↗

57

Companies Involved↗

Advanced Cancer is an emerging landscape with 16 programs across 57 companies. The most active players are Arcus Biosciences, Pfizer, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

22/100

Mech. Concentration

11/100

Completion Rate

77/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Arcus Biosciences logo

Arcus Biosciences

3 programs

Phase 1Pfizer logo

Pfizer

2 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 1A

Astex Pharmaceuticals, Inc.

1 program

Phase 1A

Avyxa

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

81%

Small molecule

13 of 16 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody319%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 94% of 17 pipeline programs.

Analysis

Trial Status

354

clinical trials

Completed227 · 64%
Terminated57 · 16%
Active, not recruiting25 · 7%
Recruiting23 · 6%
Withdrawn11 · 3%
Unknown status8 · 2%
Other3 · 1%

Clinical Trials

Trial Activity

354 trials

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Recruiting·FFox Chase Cancer Center·Phase 1·NCT04827810·42 enrolled
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
Recruiting·TTORL Biotherapeutics, LLC·Phase 1·NCT06005740·70 enrolled
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT02305654·200 enrolled
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT06091930·97 enrolled
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT05471856·66 enrolled
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Recruiting·IImmuneOncia Therapeutics Inc.·Phase 1·NCT05276310·62 enrolled
ATATcH Alternating Treatment Plans for Advanced Cancer
Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05358548·150 enrolled
Psilocybin Therapy in Advanced Cancer
Recruiting·NNYU Langone Health·Phase 2/3·NCT05398484·200 enrolled
Studying TAK-243 in Patients With Advanced Cancer
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06223542·95 enrolled
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT06882746·135 enrolled
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
Recruiting·PPharmaEngine·Phase 1·NCT05659732·32 enrolled
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Recruiting·EEpizyme, Inc.·Phase 1·NCT04241835·24 enrolled
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Recruiting·TTORL Biotherapeutics, LLC·Phase 1·NCT05103683·90 enrolled
Phase 1 Study of AWT020 in Advanced Cancer
Recruiting·AAnwita Biosciences·Phase 1·NCT06092580·60 enrolled
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
Recruiting·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 1·NCT00804154·45 enrolled
Page 1 of 24

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)